Fabbri, L.; Di Federico, A.; Astore, M.; Marchiori, V.; Rejtano, A.; Seminerio, R.; Gelsomino, F.; De Giglio, A.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics 2024, 14, 48.
https://doi.org/10.3390/diagnostics14010048
AMA Style
Fabbri L, Di Federico A, Astore M, Marchiori V, Rejtano A, Seminerio R, Gelsomino F, De Giglio A.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics. 2024; 14(1):48.
https://doi.org/10.3390/diagnostics14010048
Chicago/Turabian Style
Fabbri, Laura, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, and Andrea De Giglio.
2024. "From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)" Diagnostics 14, no. 1: 48.
https://doi.org/10.3390/diagnostics14010048
APA Style
Fabbri, L., Di Federico, A., Astore, M., Marchiori, V., Rejtano, A., Seminerio, R., Gelsomino, F., & De Giglio, A.
(2024). From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics, 14(1), 48.
https://doi.org/10.3390/diagnostics14010048
